Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 2012. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital structure notification rather than a financial results report.
Material Changes
The filing details the Company's issued share capital as of August 31, 2012:
- Total Issued Ordinary Shares: 5,472,212,817 (25p each)
- Treasury Shares: 498,408,927
- Total Voting Rights: 4,973,803,890
No material changes to financial performance or operational status are reported in this text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to statutory disclosure of share capital and voting rights.
Investor Verification Checklist
- Verify the total number of voting rights (4,973,803,890) for compliance with disclosure thresholds.
- Confirm the number of shares held in Treasury (498,408,927) as of August 31, 2012.
- Review the Company's Form 20-F or quarterly earnings releases for financial performance data not included in this filing.